Doki, YuichiroYuichiroDokiAjani, Jaffer AJaffer AAjaniKato, KenKenKatoXu, JianmingJianmingXuWyrwicz, LucjanLucjanWyrwiczMotoyama, SatoruSatoruMotoyamaOgata, TakashiTakashiOgataKawakami, HisatoHisatoKawakamiCHIH-HUNG HSUAdenis, AntoineAntoineAdenisEl Hajbi, FaridFaridEl HajbiDi Bartolomeo, MariaMariaDi BartolomeoBraghiroli, Maria IMaria IBraghiroliHoltved, EvaEvaHoltvedOstoich, Sandra ASandra AOstoichKim, Hye RHye RKimUeno, MasakiMasakiUenoMansoor, WasatWasatMansoorYang, Wen-ChiWen-ChiYangLiu, TianshuTianshuLiuBridgewater, JohnJohnBridgewaterMakino, TomokiTomokiMakinoXynos, IoannisIoannisXynosLiu, XuanXuanLiuLei, MingMingLeiKondo, KaoruKaoruKondoPatel, ApurvaApurvaPatelGricar, JosephJosephGricarChau, IanIanChauKitagawa, YukoYukoKitagawa2023-09-012023-09-012022-02-0300284793https://scholars.lib.ntu.edu.tw/handle/123456789/634901First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit over chemotherapy in previously treated patients with advanced esophageal squamous-cell carcinoma.en[SDGs]SDG3journal article10.1056/NEJMoa2111380351084702-s2.0-85124057693https://api.elsevier.com/content/abstract/scopus_id/85124057693